RxDoctor Payments Data

Relly Mer Segovia

Acute Care · Lancaster, CANPI 1780303248

Payments from drug & device makers

$2,507in general payments, 2019–2025

Across 91 payments — averaging $27.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$476
  • Gilead$370
  • Phathom Pharmaceuticals, Inc.$292
  • Ardelyx, Inc.$273
  • Madrigal Pharmaceuticals$188
  • Takeda Pharmaceuticals U.S.A., Inc.$154
  • plus $754 from 11 others

What the payments were for

  • Food & beverage$2,507100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,507 in reported general payments places this provider in the 85th percentile of 1,153 acute care providers in California.

See all acute care providers in California

Medicare billing

Part B allowed, 2024
$95,660
Medicare patients
532
Services billed
1,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase30$68,923
RezdiffraResmetirom11$60,396
LinzessLinaclotide52$39,694
Pantoprazole Sodium516$8,014
Sucralfate49$6,687
Famotidine574$4,386
CholestyramineCholestyramine (With Sugar)19$2,008
Dicyclomine Hcl64$1,748
Omeprazole136$1,599
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl46$706
Lactulose15$545
Clarithromycin18$541
Hydrocortisone30$383
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg16$356
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl16$229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$476$108,61782 claims
Madrigal PharmaceuticalsRezdiffra$188$60,39611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,153 acute care providers in California.

Other acute care in Lancaster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →